Chung Wu Investment Group LLC Makes New $173,000 Investment in Insmed, Inc. $INSM

Chung Wu Investment Group LLC purchased a new position in Insmed, Inc. (NASDAQ:INSM) in the 2nd quarter, Holdings Channel.com reports. The fund purchased 1,720 shares of the biopharmaceutical company’s stock, valued at approximately $173,000.

A number of other institutional investors have also recently made changes to their positions in INSM. 111 Capital bought a new position in shares of Insmed during the second quarter valued at about $237,000. Hilltop National Bank purchased a new stake in Insmed in the second quarter worth about $28,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Insmed by 15.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,492 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 999 shares during the last quarter. Truist Financial Corp increased its holdings in shares of Insmed by 3.1% during the second quarter. Truist Financial Corp now owns 46,483 shares of the biopharmaceutical company’s stock valued at $4,678,000 after acquiring an additional 1,409 shares in the last quarter. Finally, ORG Partners LLC increased its stake in Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares in the last quarter.

Insmed Stock Up 2.9%

NASDAQ INSM opened at $157.16 on Monday. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $158.19. The firm has a market capitalization of $33.22 billion, a price-to-earnings ratio of -27.52 and a beta of 1.03. The company has a fifty day moving average of $132.46 and a two-hundred day moving average of $99.25.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to analysts’ expectations of $104.06 million. During the same quarter in the previous year, the company posted ($1.94) earnings per share. The company’s quarterly revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Activity

In other Insmed news, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director owned 262,675 shares of the company’s stock, valued at approximately $38,190,318.25. This trade represents a 3.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of Insmed stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at approximately $7,546,758.35. The trade was a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 219,568 shares of company stock valued at $28,305,070. Company insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on INSM. Jefferies Financial Group lifted their target price on Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, August 13th. TD Cowen lifted their price objective on Insmed from $154.00 to $193.00 and gave the stock a “buy” rating in a report on Thursday. UBS Group boosted their target price on Insmed from $124.00 to $133.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Mizuho raised their price target on shares of Insmed from $130.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday, August 13th. Finally, Citigroup upgraded shares of Insmed to a “buy” rating in a research note on Tuesday, June 10th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $149.06.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.